RET (V804M/G810S)
Sign in to save this workspaceRET · Variant type: compound · HGVS: p.V804M;p.G810S
Components
p.V804Mp.G810S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 93.2% | 6.8% | 84.21 |
| 2 | Sunitinib | 89.9% | 10.1% | 91.73 |
| 3 | Capivasertib | 68.8% | 31.2% | 96.48 |
| 4 | Gilteritinib | 58.7% | 41.3% | 88.97 |
| 5 | Quizartinib | 17.3% | 82.7% | 99.50 |
| 6 | Inavolisib | 17.1% | 82.9% | 100.00 |
| 7 | Palbociclib | 2.0% | 98.0% | 98.75 |
| 8 | Darovasertib | 0.7% | 99.3% | 96.99 |
| 9 | Abemaciclib | 0.2% | 99.8% | 91.48 |
| 10 | Acalabrutinib | 0.0% | 100.0% | 99.50 |
| 11 | Cobimetinib | 0.0% | 100.0% | 100.00 |
| 12 | Canertinib | 0.0% | 100.0% | 96.49 |
| 13 | Remibrutinib | 0.0% | 100.0% | 99.50 |
| 14 | Erlotinib | 0.0% | 100.0% | 99.75 |
| 15 | Vandetanib | 0.0% | 100.0% | 95.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 93.2% | — | — |
| Sunitinib | 89.9% | 97.2% | -7.3% |
| Capivasertib | 68.8% | — | — |
| Gilteritinib | 58.7% | 100.0% | -41.3% |
| Quizartinib | 17.3% | — | — |
| Inavolisib | 17.1% | — | — |
| Palbociclib | 2.0% | — | — |
| Darovasertib | 0.7% | — | — |
| Abemaciclib | 0.2% | — | — |
| Acalabrutinib | 0.0% | — | — |
| Cobimetinib | 0.0% | — | — |
| Canertinib | 0.0% | — | — |
| Remibrutinib | 0.0% | — | — |
| Erlotinib | 0.0% | — | — |
| Vandetanib | 0.0% | 98.6% | -98.6% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms